

Corporate Profile

Meridian is a fully integrated life science company that develops, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Primary IR Contact

Melissa Lueke
Executive Vice President
Chief Financial Officer
Meridian Bioscience, Inc.

Stock Performance

VIVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$14.85
Change (%)	▼ 0.05 (0.34%)
Volume	187,078
52 Week Low	\$12.70
Market Cap	\$630,385,356
Rolling EPS	0.57
PE Ratio	26.3149
Shares Outstanding	42,307,742

Data as of 03/20/18 4:00 p.m. ET



Recent Press Releases

- 1/25/2018
Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
- 1/19/2018
Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018
- 11/9/2017
Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance
- 10/23/2017
Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics
- 10/19/2017
Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance

Upcoming Events

There are currently no events scheduled.

Recent SEC Filings

Filing Date	Form	Description
03/12/18	SC 13G/A	An amendment to the SC 13G filing
02/26/18	8-K	Report of unscheduled material events or corporate event
02/26/18	4	Statement of changes in beneficial ownership of securities
02/14/18	SC 13G/A	An amendment to the SC 13G filing

Analyst Estimates / Ratings

Mean Recommendation: **3.3**



Unable to fulfill request.

Management

John A. Kraeutler
Executive Chairman

Jack P. Kenny
Chief Executive Officer

Lawrence J. Baldini
Executive Vice President and President, Global Operations

Marco Calzavara
President, Meridian Bioscience Europe

Melissa A. Lueke
Executive Vice President, Chief Financial Officer

Susan D. Rolih
Executive Vice President, Regulatory Affairs and Quality Assurance

Lourdes G. Weltzien
Vice President & General Manager, President Asia Pacific Markets

Amy M. Winslow
Executive Vice President, President and CEO Magellan Diagnostics

Board of Directors

John A. Kraeutler
Executive Chairman

Jack Kenny
Chief Executive Officer

James M. Anderson
Retired President and Chief Executive Officer Cincinnati Children's Hospital Medical Center

Dwight E. Ellingwood
President, D.E.E. Strategy Consulting, LLC

David C. Phillips
Co-founder Cincinnati Works, Inc

John C. McIlwraith
Co-founder Allos Ventures

John M. Rice
Founder and Managing Partner of Triathlon Medical Venture Partners

Catherine A. Sazdanoff
Chief Business Officer of Strata Oncology, Inc

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	260	557.43	94.0	39,762,023
Mutual Fund	287	308.62	49.0	20,728,798
Insider *	15	14.87	2.4	995,990

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	4,948,156	11.7	90,852	12/31/17
Brown Capital Management, LLC	4,665,143	11.0	-828,323	12/31/17
The Vanguard Group, Inc.	4,258,302	10.1	53,974	02/28/18
Renaissance Technologies LLC	2,230,676	5.3	178,900	12/31/17
Dimensional Fund Advisors, L.P.	1,787,707	4.2	38,859	12/31/17
State Street Global Advisors (US)	1,254,149	3.0	49,825	12/31/17
Norges Bank Investment Management (NBIM)	1,136,022	2.7	0	12/31/17
Millennium Management LLC	1,133,765	2.7	402,430	12/31/17
New York State Common Retirement Fund	1,058,987	2.5	-1,000	12/31/17
M & G Investment Management Ltd.	923,400	2.2	0	12/31/17

Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Minimum 20 minutes delayed